Novartis invests $300M to grow biologics portfolio

Sept. 13, 2022

Novartis is looking to ride the biologics wave, revealing this week that it will be investing $300 million to help create a scientific environment that will “bolster its capacities and capabilities for early technical development of biologics.”

The Swiss-American pharma says that it has been working on growing its biologics portfolio in the last 15 years and that this new investment will allow them to build the research environment necessary to develop the compounds from the bench through development in an integrated way. 

The recent press release also outlined that $100 million will go toward a biologics hub in the Novartis St. Johann campus, $110 million will be invested in a new biocampus in Mengeš, Slovenia for clinical manufacturing capabilities (both cGMP and non cGMP), and approximately $60 million will be used to develop manufacturing capabilities in its Schaftenau campus in Austria. 

Recently, Novartis announced its intention to separate Sandoz, its generics and biosimilars division, into a new publicly traded standalone company.